Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and PK of Domestic Gefitinib vs Iressa in NSCLC
NCT03264794Phase 4Unknown
- Sponsor
- Jiangsu Famous Medical Technology
- Start
- Aug 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiangsu Famous Medical Technology. Primary endpoints: Gefitinib plasma concentration at 168 hours, Time to Maximum Plasma Concentration and 3 more. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03264794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264794.